The Cannabis Use Disorder market is witnessing significant advancements driven by novel therapeutic developments and increasing awareness of substance abuse disorders. This industry, shaped by evolving regulations and enhanced treatment options, is poised for substantial business growth and growing market revenue, reflecting increasing healthcare focus globally.
Market Size and Overview
The cannabis use disorder market is estimated to be valued at USD 1.80 Bn in 2025 and is expected to reach USD 3.40 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.5% from 2025 to 2032.
The Cannabis Use Disorder Market forecast highlights an expanding industry size propelled by innovative pharmacological solutions and rising diagnosis rates worldwide. Increased clinical trials and regulatory approvals for targeted therapies continue to enlarge the market scope, reflecting evolving market dynamics and enhanced market opportunities.
Key Takeaways
- Dominating Region: North America leads the Cannabis Use Disorder market share in 2025, supported by comprehensive healthcare infrastructure and pioneering research in addiction therapy. For example, pharmaceutical advancements in the U.S. have underscored market growth strategies.
- Fastest Growing Region: Asia-Pacific is the fastest-growing region, benefiting from increasing healthcare investments and rising awareness programs.
- By Treatment Type:
- Dominant Sub-segment: Pharmacotherapy remains dominant, driven by drugs like cannabidiol-based treatments developed by leading market players.
- Fastest Growing Sub-segment: Behavioral therapy is gaining momentum, as seen in recent integrative treatment models piloted in Europe in 2024.
- By Distribution Channel:
- Dominant Sub-segment: Hospital pharmacies retain dominance due to high patient inflow and specialist availability.
- Fastest Growing Sub-segment: Online pharmacies, boosted by digital healthcare trends, particularly post-pandemic.
- By End User:
- Dominant Sub-segment: Addiction treatment centers remain the primary end-users for therapeutic interventions.
- Fastest Growing Sub-segment: Outpatient care settings, driven by cost-effective treatment models.
Market Key Trends
One pivotal market trend shaping the Cannabis Use Disorder market in 2025 is the surge in adoption of cannabinoid-based pharmacotherapies, marked by significant R&D investments and regulatory approvals. For example, advancements in cannabidiol (CBD) formulations by companies such as Pfizer and Corbus Pharmaceuticals have introduced new treatment options with better safety profiles.
The U.S. FDA’s expanded acceptance of CBD therapies for substance use disorders has accelerated product launches and clinical trials, reinforcing market drivers and sustaining upward market growth. This trend is supported by real-world outcomes reported in clinical studies from 2024, evidencing improved patient compliance and reduced relapse rates. These developments underscore the evolving market analysis and the dynamic regulatory landscape that create substantial market opportunities while addressing market challenges related to stigma and access.
Key Players
Prominent market players operating in the Cannabis Use Disorder market include Aelis Farma, Indivior, Pfizer, Corbus Pharmaceuticals, and Zynerba Pharmaceuticals. These market companies are actively pursuing innovation and collaboration to strengthen their industry share and market revenue. Strategies include:
- Expanding global footprint through strategic partnerships in Asia-Pacific and Europe (e.g., Pfizer’s collaboration with regional research institutes in 2024).
- Launching novel synthetic cannabinoid products and improving drug delivery systems to enhance efficacy and patient adherence.
- Investing extensively in clinical trials to secure approvals, demonstrated by Indivior’s late-stage trial results in 2025 showing promising outcomes.
These efforts have collectively facilitated increased market growth and fortified competitive positioning amidst evolving market dynamics.
FAQs on Cannabis Use Disorder Market
1. Who are the dominant players in the Cannabis Use Disorder market?
Key market players include Aelis Farma, Indivior, Pfizer, Corbus Pharmaceuticals, and Zynerba Pharmaceuticals, which lead through innovative product pipelines and strategic global expansions.
2. What will be the size of the Cannabis Use Disorder market in the coming years?
The market is projected to grow from USD 1.80 billion in 2025 to approximately USD 3.40 billion by 2032, exhibiting a CAGR of 10%.
3. Which end user segment holds the largest growth opportunity in this market?
Addiction treatment centers currently dominate, but outpatient care is recognized as the fastest-growing segment due to outpatient therapy models gaining traction.
4. How will market development trends evolve over the next five years?
Market trends will be largely shaped by the advancement of cannabinoid-based therapies and increasing integration of behavioral treatments, along with digital distribution channels enhancing accessibility.
5. What is the nature of the competitive landscape and key challenges in the Cannabis Use Disorder market?
The competitive landscape is defined by innovation-led strategies amid regulatory complexities and challenges such as stigma, limited access in developing regions, and high treatment costs.
6. What go-to-market strategies are commonly adopted in the Cannabis Use Disorder market?
Common strategies include forming strategic partnerships for clinical research, expanding geographic reach, focusing on product innovation, and leveraging digital health platforms for patient outreach.
‣ Get this Report in Japanese Language : 大麻使用障害市場
‣ Get this Report in Korean Language : 대마사용장애시장
‣ Read More Related Articles : Global EYLEA Drug - A Breakthrough In Treatment Of Retinal Diseases
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )
Comments
0 comment